B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model
Abstract Background Peptide immunotherapy (PIT) offers a safe and effective treatment with minimal side effects. This study aims to identify B-cell epitopes of a novel allergen from Blomia tropicalis (B. tropicalis), specifically the Chitin-binding domain type 2 (ChtBD2) protein, and evaluate the th...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Respiratory Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12931-025-03207-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184664363302912 |
|---|---|
| author | Jiale Zhang Wenting Luo YuBao Cui Baoqing Sun |
| author_facet | Jiale Zhang Wenting Luo YuBao Cui Baoqing Sun |
| author_sort | Jiale Zhang |
| collection | DOAJ |
| description | Abstract Background Peptide immunotherapy (PIT) offers a safe and effective treatment with minimal side effects. This study aims to identify B-cell epitopes of a novel allergen from Blomia tropicalis (B. tropicalis), specifically the Chitin-binding domain type 2 (ChtBD2) protein, and evaluate the therapeutic effects of peptide treatment in a murine model. Methods Using Alphafold2, the 3D structure of ChtBD2 was constructed. AI-based and traditional computational tools predicted the predominant B-cell epitopes. Twelve synthesized peptides were assessed for allergenicity and immunogenicity. A murine model of B. tropicalis-induced allergic airway inflammation mimicking human atopic asthma was developed and analyzed. Results Predominant B-cell epitopes of ChtBD2 were identified as promising IgE-binding domains. Peptide 1 (PT1: 1–15) showed significant IgE-binding activity and the highest inhibition rate in competitive IgE-binding assays. PT1 upregulated IL-4, IL-13, and CD63 in B. tropicalis-sensitized patients’ PBMCs and basophils, respectively. Notably, IT groups showed reduced lung cellular infiltration and type 2 cytokine expression in BALF. Specific IgE levels were reduced, with a decline in the IgG1/IgG2a ratio. Conclusions This study represents the first AI-facilitated development of a B-cell epitope-based ChtBD2 PIT, showing promise as an immunotherapy for B. tropicalis-allergic patients with reduced allergenicity and high immunogenicity in inducing IgG-blocking antibodies. Clinical trial Not applicable. |
| format | Article |
| id | doaj-art-4a77bdc19d424bfb8ffe56e5aa44468b |
| institution | OA Journals |
| issn | 1465-993X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj-art-4a77bdc19d424bfb8ffe56e5aa44468b2025-08-20T02:16:59ZengBMCRespiratory Research1465-993X2025-04-0126111410.1186/s12931-025-03207-8B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine modelJiale Zhang0Wenting Luo1YuBao Cui2Baoqing Sun3Department of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical UniversityDepartment of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical UniversityClinical Research Center, The Affiliated Wuxi People’s Hospital of Nanjing Medical UniversityDepartment of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical UniversityAbstract Background Peptide immunotherapy (PIT) offers a safe and effective treatment with minimal side effects. This study aims to identify B-cell epitopes of a novel allergen from Blomia tropicalis (B. tropicalis), specifically the Chitin-binding domain type 2 (ChtBD2) protein, and evaluate the therapeutic effects of peptide treatment in a murine model. Methods Using Alphafold2, the 3D structure of ChtBD2 was constructed. AI-based and traditional computational tools predicted the predominant B-cell epitopes. Twelve synthesized peptides were assessed for allergenicity and immunogenicity. A murine model of B. tropicalis-induced allergic airway inflammation mimicking human atopic asthma was developed and analyzed. Results Predominant B-cell epitopes of ChtBD2 were identified as promising IgE-binding domains. Peptide 1 (PT1: 1–15) showed significant IgE-binding activity and the highest inhibition rate in competitive IgE-binding assays. PT1 upregulated IL-4, IL-13, and CD63 in B. tropicalis-sensitized patients’ PBMCs and basophils, respectively. Notably, IT groups showed reduced lung cellular infiltration and type 2 cytokine expression in BALF. Specific IgE levels were reduced, with a decline in the IgG1/IgG2a ratio. Conclusions This study represents the first AI-facilitated development of a B-cell epitope-based ChtBD2 PIT, showing promise as an immunotherapy for B. tropicalis-allergic patients with reduced allergenicity and high immunogenicity in inducing IgG-blocking antibodies. Clinical trial Not applicable.https://doi.org/10.1186/s12931-025-03207-8B-cell epitopesPeptide immunotherapyBlomia tropicalisChitin-binding domain type 2 (ChtBD2) proteinArtificial intelligence |
| spellingShingle | Jiale Zhang Wenting Luo YuBao Cui Baoqing Sun B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model Respiratory Research B-cell epitopes Peptide immunotherapy Blomia tropicalis Chitin-binding domain type 2 (ChtBD2) protein Artificial intelligence |
| title | B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model |
| title_full | B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model |
| title_fullStr | B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model |
| title_full_unstemmed | B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model |
| title_short | B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model |
| title_sort | b cell epitope peptide immunotherapy alleviates chitin binding protein induced type 2 airway inflammation in a blomia tropicalis murine model |
| topic | B-cell epitopes Peptide immunotherapy Blomia tropicalis Chitin-binding domain type 2 (ChtBD2) protein Artificial intelligence |
| url | https://doi.org/10.1186/s12931-025-03207-8 |
| work_keys_str_mv | AT jialezhang bcellepitopepeptideimmunotherapyalleviateschitinbindingproteininducedtype2airwayinflammationinablomiatropicalismurinemodel AT wentingluo bcellepitopepeptideimmunotherapyalleviateschitinbindingproteininducedtype2airwayinflammationinablomiatropicalismurinemodel AT yubaocui bcellepitopepeptideimmunotherapyalleviateschitinbindingproteininducedtype2airwayinflammationinablomiatropicalismurinemodel AT baoqingsun bcellepitopepeptideimmunotherapyalleviateschitinbindingproteininducedtype2airwayinflammationinablomiatropicalismurinemodel |